JP2020505044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505044A5 JP2020505044A5 JP2019540095A JP2019540095A JP2020505044A5 JP 2020505044 A5 JP2020505044 A5 JP 2020505044A5 JP 2019540095 A JP2019540095 A JP 2019540095A JP 2019540095 A JP2019540095 A JP 2019540095A JP 2020505044 A5 JP2020505044 A5 JP 2020505044A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- genetically modified
- protein
- composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 108700019146 Transgenes Proteins 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 230000002950 deficient Effects 0.000 claims description 8
- 238000002641 enzyme replacement therapy Methods 0.000 claims description 8
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 6
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 6
- 239000003114 blood coagulation factor Substances 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 4
- 108010076282 Factor IX Proteins 0.000 claims description 4
- 208000031220 Hemophilia Diseases 0.000 claims description 4
- 208000009292 Hemophilia A Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 229960004222 factor ix Drugs 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108091008875 B cell receptors Proteins 0.000 claims description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 101000634835 Homo sapiens M1-specific T cell receptor alpha chain Proteins 0.000 claims description 2
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 claims description 2
- 101000634836 Homo sapiens T cell receptor alpha chain MC.7.G5 Proteins 0.000 claims description 2
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 2
- 102100029450 M1-specific T cell receptor alpha chain Human genes 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 claims description 2
- 230000006023 anti-tumor response Effects 0.000 claims description 2
- 230000005875 antibody response Effects 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 230000008499 blood brain barrier function Effects 0.000 claims description 2
- 239000003130 blood coagulation factor inhibitor Substances 0.000 claims description 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000003915 cell function Effects 0.000 claims description 2
- 230000008614 cellular interaction Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 238000012239 gene modification Methods 0.000 claims description 2
- 230000005017 genetic modification Effects 0.000 claims description 2
- 235000013617 genetically modified food Nutrition 0.000 claims description 2
- 210000001280 germinal center Anatomy 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 210000002707 regulatory b cell Anatomy 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims description 2
- 230000014616 translation Effects 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022173206A JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762450917P | 2017-01-26 | 2017-01-26 | |
| US62/450,917 | 2017-01-26 | ||
| PCT/US2018/015180 WO2018140573A1 (en) | 2017-01-26 | 2018-01-25 | B-cell engineering |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173206A Division JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505044A JP2020505044A (ja) | 2020-02-20 |
| JP2020505044A5 true JP2020505044A5 (OSRAM) | 2020-12-17 |
Family
ID=62979713
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540095A Withdrawn JP2020505044A (ja) | 2017-01-26 | 2018-01-25 | Ｂ細胞操作 |
| JP2022173206A Pending JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173206A Pending JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190352614A1 (OSRAM) |
| EP (1) | EP3573464A4 (OSRAM) |
| JP (2) | JP2020505044A (OSRAM) |
| KR (1) | KR20190111063A (OSRAM) |
| CN (1) | CN110536963A (OSRAM) |
| AU (1) | AU2018212652B2 (OSRAM) |
| BR (1) | BR112019015355A2 (OSRAM) |
| CA (1) | CA3051113A1 (OSRAM) |
| IL (1) | IL268110B2 (OSRAM) |
| MX (1) | MX2019008844A (OSRAM) |
| WO (1) | WO2018140573A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| EP3573464A4 (en) * | 2017-01-26 | 2020-12-30 | Sangamo Therapeutics, Inc. | B CELL ENGINEERING |
| AU2018235957B2 (en) * | 2017-03-16 | 2024-02-01 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| BR112021007301A2 (pt) | 2018-10-18 | 2021-07-27 | Intellia Therapeutics, Inc. | composições e métodos para expressar fator ix |
| WO2021085504A1 (ja) * | 2019-11-01 | 2021-05-06 | 京都府公立大学法人 | Ｂ細胞抗体受容体、及びその利用 |
| EP4127188A4 (en) | 2020-03-31 | 2024-08-21 | Walking Fish Therapeutics | MODIFIED B CELLS AND METHODS OF USE THEREOF |
| WO2023192936A2 (en) * | 2022-03-30 | 2023-10-05 | Fred Hutchinson Cancer Center | Systems and methods to produce b cells that express selected antibodies and gene products |
| WO2024151683A2 (en) * | 2023-01-09 | 2024-07-18 | Walking Fish Therapeutics, Inc. | HUMAN B CELL ENGINEERED TO EXPRESS IgA AND IgM ANTIBODIES FOR THERAPEUTIC USE |
| WO2024196669A2 (en) * | 2023-03-17 | 2024-09-26 | Walking Fish Therapeutics, Inc. | Methods for in vivo editing of b cells |
| WO2024220447A2 (en) * | 2023-04-17 | 2024-10-24 | Be Biopharma, Inc. | Engineered cell preparations for treatment of niemann pick b disease |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003901511A0 (en) * | 2003-03-28 | 2003-04-17 | Bionomics Limited | Nucleic acid molecules associated with angiogenesis II |
| DK1804839T3 (da) * | 2004-09-22 | 2012-04-10 | St Jude Childrens Res Hospital | Forbedret ekspression af faktor ix i genterapivektorer |
| US9834787B2 (en) * | 2009-04-09 | 2017-12-05 | Sangamo Therapeutics, Inc. | Targeted integration into stem cells |
| AU2014265331B2 (en) * | 2013-05-15 | 2019-12-05 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
| US9757420B2 (en) * | 2014-07-25 | 2017-09-12 | Sangamo Therapeutics, Inc. | Gene editing for HIV gene therapy |
| CN106795488B (zh) * | 2014-09-16 | 2021-03-30 | 桑格摩治疗股份有限公司 | 用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物 |
| EP4177336A1 (en) * | 2014-12-19 | 2023-05-10 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents |
| EP4335918A3 (en) * | 2015-04-03 | 2024-04-17 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| HUE066300T2 (hu) * | 2015-06-24 | 2024-07-28 | Janssen Biotech Inc | Immunmoduláció és szolid tumorok kezelése CD38-hoz specifikusan kötõdõ antitestekkel |
| WO2017011519A1 (en) * | 2015-07-13 | 2017-01-19 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| EP3402533B1 (en) * | 2016-01-15 | 2021-08-04 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of neurologic disease |
| EP3573464A4 (en) * | 2017-01-26 | 2020-12-30 | Sangamo Therapeutics, Inc. | B CELL ENGINEERING |
| CN111533799A (zh) * | 2017-04-10 | 2020-08-14 | 伊玛提克斯生物技术有限公司 | 用于白血病和其他癌症免疫治疗的肽和肽组合物 |
| WO2018232296A1 (en) * | 2017-06-16 | 2018-12-20 | Sangamo Therapeutics, Inc. | Targeted disruption of t cell and/or hla receptors |
| MX2020001594A (es) * | 2017-08-08 | 2020-12-09 | Sangamo Therapeutics Inc | Direccionamiento celular mediado por receptor de antigeno quimerico. |
| CN111565730B (zh) * | 2017-11-09 | 2024-09-17 | 桑格摩生物治疗股份有限公司 | 细胞因子诱导型含sh2蛋白（cish）基因的遗传修饰 |
| US20230158070A1 (en) * | 2018-01-30 | 2023-05-25 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
| AU2019327913A1 (en) * | 2018-08-29 | 2021-03-18 | Nanjing Legend Biotech Co., Ltd. | Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof |
| CN113748126A (zh) * | 2018-11-30 | 2021-12-03 | 因提玛生物科学公司 | 鉴定免疫调节基因的方法 |
-
2018
- 2018-01-25 EP EP18744407.0A patent/EP3573464A4/en active Pending
- 2018-01-25 CA CA3051113A patent/CA3051113A1/en active Pending
- 2018-01-25 US US16/480,939 patent/US20190352614A1/en not_active Abandoned
- 2018-01-25 MX MX2019008844A patent/MX2019008844A/es unknown
- 2018-01-25 JP JP2019540095A patent/JP2020505044A/ja not_active Withdrawn
- 2018-01-25 KR KR1020197023790A patent/KR20190111063A/ko not_active Ceased
- 2018-01-25 AU AU2018212652A patent/AU2018212652B2/en not_active Ceased
- 2018-01-25 IL IL268110A patent/IL268110B2/en unknown
- 2018-01-25 WO PCT/US2018/015180 patent/WO2018140573A1/en not_active Ceased
- 2018-01-25 CN CN201880021264.1A patent/CN110536963A/zh active Pending
- 2018-01-25 BR BR112019015355A patent/BR112019015355A2/pt not_active IP Right Cessation
-
2022
- 2022-10-28 JP JP2022173206A patent/JP2022191524A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505044A5 (OSRAM) | ||
| JP2017500061A5 (OSRAM) | ||
| Kumar et al. | Clinical development of gene therapy: results and lessons from recent successes | |
| Xi et al. | Genetically engineered pigs for xenotransplantation: Hopes and challenges | |
| JP2020500162A5 (OSRAM) | ||
| Wolf et al. | Beyond vascular inflammation—recent advances in understanding atherosclerosis | |
| JP2016539627A5 (OSRAM) | ||
| De Ciuceis et al. | Immune mechanisms in hypertension | |
| Kohn | Gene therapy for blood diseases | |
| JP2017504354A5 (OSRAM) | ||
| JP2021505187A (ja) | 遺伝子編集のためのｃｐｆ１関連方法及び組成物 | |
| Bueren et al. | Advances in the gene therapy of monogenic blood cell diseases | |
| Naeimi Kararoudi et al. | Clustered regularly interspaced short palindromic repeats/Cas9 gene editing technique in xenotransplantation | |
| Paladini et al. | The multifaceted nature of aminopeptidases ERAP1, ERAP2, and LNPEP: from evolution to disease | |
| US12385070B2 (en) | Homology directed repair compositions for the treatment of hemoglobinopathies | |
| Shi et al. | Platelets as delivery systems for disease treatments | |
| ES3032739T3 (en) | Genetically engineered hematopoietic stem cell as a platform for systemic protein expression | |
| Ly et al. | Gene therapy in the treatment of heart failure | |
| AU2019234922A1 (en) | Systems and methods for the treatment of hemoglobinopathies | |
| Kyriakopoulou et al. | Gene editing innovations and their applications in cardiomyopathy research | |
| Bottino et al. | Use of genetically-engineered pig donors in islet transplantation | |
| Hodge et al. | Wide awake and ready to move: 20 years of non-viral therapeutic genome engineering with the sleeping beauty transposon system | |
| Wilcox | Megakaryocyte-and megakaryocyte precursor–related gene therapies | |
| Lidonnici et al. | Gene therapy for hemoglobinopathies | |
| Urnov | The Cas9 hammer—and sickle: a challenge for genome editors |